ジェネリック医薬品・バイオシミラー医薬品用CRO規制サービスの世界市場2020-2030

【英語タイトル】CRO Regulatory Services for Generics and Biosimilars Drugs Market Report 2020-2030

visiongainが出版した調査資料(VGA20DE021)・商品コード:VGA20DE021
・発行会社(調査会社):visiongain
・発行日:2020年9月
・ページ数:506
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)USD5,850 ⇒換算¥608,400見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,099 ⇒換算¥946,296見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Discover sales predictions for the world market and submarkets• By Services
• Regulatory Writing and Publishing
• Clinical Trial Application and Product Registration
• Regulatory Consulting
• Legal Representation
• Other Regulatory Services
• By Application
• Oncology
• Cardiology
• Infectious Disease
• Metabolic Disorders
• Others
• By Clinical Phase
• Preclinical
• Phase I
• Phase II
• Phase III
• Phase IV
• By End User
• Pharmaceutical Companies
• Biotechnology Companies
• Government Institutes
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 16 leading national markets:
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• South Africa
• Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the CRO Regulatory Services for Generics and Biosimilar Drugs Market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and India, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Overall world revenue for CRO Regulatory Services for Generics and Biosimilar Drugs Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the CRO Regulatory Services for Generics and Biosimilar Drugs Market report helps you

In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for CRO Regulatory Services for Generics and Biosimilar Drugs Market, with forecasts for Technology and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 5 regional and 16 key national markets – See forecasts for the CRO Regulatory Services for Generics and Biosimilar Drugs market in North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada,, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, GCC Countries and South Africa.
• Prospects for established firms and those seeking to enter the market– including company profiles for 11 of the major companies involved in the CRO Regulatory Services for Generics and Biosimilar Drugs Market. Some of the company’s profiles in this report include:
• IQVIA (Quintiles Transnational)
• ICON plc
• Pharmaceutical Product Development (PPD)
• Covance, Inc.
• Genpact Ltd.
• Criterium, Inc.
• Accell Clinical Research
• Charles River Laboratories International
• Medpace, Inc.
• Wuxi AppTec.
• Syneos Health
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

【レポートの目次】

1. Report Overview
1.1 Overview of CRO Regulatory Services for Generics and Biosimilars Drugs: R&D, Industry and Market
1.2 Why You Should Read this Report
1.3 How This Study Delivers
1.4 Main Questions Answered by the Analysis
1.5 Who is This Investigation For?
1.6 Method of Research and Analysis
1.7 Recovery Scenarios
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Executive Summary
2.1 Key Market Facts: CRO regulatory services for generics and biosimilars drugs 2019-2030
2.2 Geographical Scenario
2.3 Companies in the Market
3. Introduction to CRO Regulatory Services for Generics and Biosimilars Drugs
3.1 What are Contract Research Organizations (CROs)
3.2 CRO Services
3.2.1 Medical Function
3.2.2 Regulatory Application Team
3.2.3 Clinical Operations
3.2.4 Data management:
3.2.5 Biostatistics
3.2.6 Medical Writing
3.2.7 Quality Assurance
3.3 Importance of Outsourcing CRO Services
4. CRO Regulatory Services for Generics and Biosimilar Drugs: Qualitative Analysis 2020-2030
4.1 Market Drivers Analysis: 2020-2030
4.1.1 Growing Demand for Contract Manufacturing Services
4.1.2 Focus On Core Competencies By Pharmaceutical and Biopharmaceutical Companies
4.1.3 Rise in Demand for Biosimilars and Generics
4.2 Market Restraints Analysis: 2020-2030
4.2.1 Project Delays and Cancellations
4.2.2 Shortage of Skilled Professionals
4.3 Market Opportunities Analysis: 2020-2030
4.3.1 Favourable Shift of Regulatory Landscape
4.3.2 Pricing Pressures and Intense Competition Among Pharmaceutical and Biopharmaceutical Companies
4.3.3 CROs in Emerging Market
4.4 Market Trends: 2020-2030
4.4.1 Advantages of Outsourcing
4.4.2 Growing Trend to Outsource the Regulatory Affairs
5. CRO Regulatory Services Industry Study, 2020-2030
5.1 CRO Regulatory Services Industry: Porters Five Forces Analysis, 2020-2030
5.1.1 Bargaining Power of Supplier: Low
5.1.2 Bargaining Power of Buyer: Moderate
5.1.3 Competitive Rivalry: High
5.1.4 Threat of New Entrants: Moderate
5.1.5 Threat of Substitutes: Low
5.2 SWOT Analysis
5.2.1 Strengths
5.2.1.1 Outsourcing Improves Time to Launch Product in the Market
5.2.1.2 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
5.2.1.3 Adoption of Biosimilar will be Proportional to the Rate of Discount
5.2.1.4 Approval Pathways are Now Established in Developed Markets
5.2.1.5 Manufacturers Get Access to Specialised Technologies
5.2.1.6 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
5.2.2 Weaknesses
5.2.2.1 Complexity of Protein Molecules Leads to Technical Challenges
5.2.2.2 Doctor and Patient Confidence May Take Time
5.2.3 Opportunities
5.2.3.1 Dynamic Change: Emerging Markets are Major Biosimilar Developers
5.2.3.2 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
5.2.3.3 Many Companies Cannot Afford In-house Capabilities
5.2.3.4 Changing World Demographics
5.2.4 Threats
5.2.4.1 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
5.3 Regulatory Framework Analysis
5.4 PEST Analysis: CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
5.4.1 Political Issues: Stringent Regulations Hurdles to Market Entry
5.4.2 Economic Pressures Raise Demand for Generic and Biosimilar Drugs
5.4.2.1 Fragmentation of the Market Could Limit Individual Revenues
5.4.3 Social Factors: Driving or Restraining the Market?
5.4.4 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
6. CRO Regulatory Services for Generics and Biosimilars Drugs Market: Impact of COVID-19
7. Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Landscape 2020-2030
7.1 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market
7.1.1 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
7.2 Market Share Analysis By Services
7.3 Market Share Analysis By Region 2020-2030
8. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, 2020-2030
8.1 Market Overview
8.2 CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, Market Forecast 2020-2030
8.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, 2020-2030
8.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
8.3.1 Regulatory Writing and Publishing
8.3.2 Clinical Trial Application and Product Registration
8.3.3 Regulatory Consulting
8.3.4 Legal Representation
8.3.5 Other Regulatory Affairs
9. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020-2030
9.1 Market Overview
9.2 Market Forecast 2020-2030
9.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020-2030
9.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
9.3.1 Oncology
9.3.2 Cardiology
9.3.3 Infectious Diseases
9.3.4 Metabolic Disorders
9.3.5 Other Applications
10. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020-2030
10.1 Market Overview
10.2 Market Forecast 2020-2030
10.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020-2030
10.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
10.3.1 Pre-clinical Phase
10.3.2 Phase I
10.3.3 Phase II
10.3.4 Phase III
10.3.5 Phase IV
11. CRO Regulatory Services for Generics and Biosimilar Drugs Market by End User, 2020-2030
11.1 Market Overview
11.2 Market Forecast 2020-2030
11.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by End Use, 2020-2030
11.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
11.3.1 Pharmaceutical Companies
11.3.2 Biotechnology Companies
11.3.3 Government Institutes
11.3.4 Others
12. Leading National Markets 2020-2030
12.1 Geographical Breakdown of the World CRO Regulatory Services for Generics and Biosimilars Drugs Market
12.2 Global CRO Regulatory Services for Generics and Biosimilars Drugs Market: Regional Forecast 2020-2030
12.3 How Will Regional Market Shares Change by 2030?
13. North America CRO Regulatory Services for Generics and Biosimilars Drugs Market, 2020-2030
13.1 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
13.1.1 Recovery Scenarios (V, U, W, L): North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
13.2 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
13.2.1 Recovery Scenarios (V,U,W,L): North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
13.3 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
13.3.1 Recovery (V,U,W,L) Scenarios: North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
13.4 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
13.4.1 Recovery (V,U,W,L) Scenarios: North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
13.5 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
13.6 US CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
13.6.1 U.S. CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
13.7 Canada CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
13.7.1 Canada CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14. Europe CRO Regulatory Services for Generics and Biosimilars Drugs Market, 2020-2030
14.1 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
14.1.1 Recovery Scenarios (V, U, W, L): Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
14.2 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
14.2.1 Recovery Scenarios (V,U,W,L): Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
14.3 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
14.3.1 Recovery (V,U,W,L) Scenarios: Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
14.4 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
14.4.1 Recovery (V,U,W,L) Scenarios: Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
14.5 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.6 Germany CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.6.1 Germany CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.7 UK CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.7.1 UK CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.8 French CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.8.1 French CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.9 Italian CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.9.1 Italian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.10 Spanish CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.10.1 Spanish CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.11 Russia CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.11.1 Russian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
14.12 Rest of Europe CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
14.12.1 Rest of Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15. Asia Pacific CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
15.1 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
15.1.1 Recovery Scenarios (V, U, W, L): Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
15.2 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
15.2.1 Recovery Scenarios (V,U,W,L): Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
15.3 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
15.3.1 Recovery (V,U,W,L) Scenarios: Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
15.4 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
15.4.1 Recovery (V,U,W,L) Scenarios: Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
15.5 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15.6 Japanese CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
15.6.1 Japanese CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15.7 Chinese CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
15.7.1 Chinese CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15.8 Indian CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
15.8.1 Indian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15.9 Australia CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
15.9.1 Australia CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
15.10 Rest of Asia Pacific CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
15.10.1 Rest of Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
16. Latin America CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
16.1 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
16.1.1 Recovery Scenarios (V, U, W, L): Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
16.2 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
16.2.1 Recovery Scenarios (V,U,W,L): Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
16.3 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
16.3.1 Recovery (V,U,W,L) Scenarios: Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
16.4 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
16.4.1 Recovery (V,U,W,L) Scenarios: Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
16.5 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
16.6 Brazilian CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
16.6.1 Brazilian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
16.7 Mexico CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
16.7.1 Mexican CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
16.8 Rest of Latin America CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
16.8.1 Rest of Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
17. MEA CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
17.1 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
17.1.1 Recovery Scenarios (V, U, W, L): MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
17.2 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
17.2.1 Recovery Scenarios (V,U,W,L): MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
17.3 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
17.3.1 Recovery (V,U,W,L) Scenarios: MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
17.4 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
17.4.1 Recovery (V,U,W,L) Scenarios: MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
17.5 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
17.6 GCC CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
17.6.1 GCC CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
17.7 South Africa CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
17.7.1 South Africa CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
17.8 Rest of MEA CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
17.8.1 Rest of MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
18. Leading Companies in the CRO Regulatory Services for Generics and Biosimilars Drugs Market
18.1 IQVIA
18.1.1 IQVIA: Company Snapshot
18.1.2 IQVIA: Company Overview
18.1.3 IQVIA: Financials, 2015-2019
18.1.4 IQVIA: Services
18.1.5 IQVIA: Recent Developments
18.2 ICON plc.
18.2.1 ICON plc.: Company Snapshot
18.2.2 ICON plc.: Company Overview
18.2.3 ICON plc.: Financial Overview 2015-2019
18.2.4 ICON plc.: Services Portfolio
18.2.5 ICON plc.: Recent Developments
18.3 Pharmaceutical Product Development (PPD)
18.3.1 Pharmaceutical Product Development (PPD): Company Snapshot
18.3.2 Pharmaceutical Product Development (PPD): Company Overview
18.3.3 Pharmaceutical Product Development (PPD): Services Portfolio
18.3.4 Pharmaceutical Product Development (PPD): Recent Developments
18.4 Covance Inc.
18.4.1 Covance Inc.: Company Snapshot
18.4.2 Covance Inc.: Company Overview
18.4.3 Covance Inc.: Financial Overview
18.4.4 Covance Inc.: Services Portfolio
18.4.5 Covance Inc.: Recent Developments
18.5 Genpact Ltd.
18.5.1 Genpact Ltd.: Company Snapshot
18.5.2 Genpact Ltd.: Company Overview
18.5.3 Genpact Ltd.: Financial Overview
18.5.4 Genpact Ltd.: Services Portfolio
18.5.5 Genpact Ltd.: Recent Developments
18.6 Criterium Inc.
18.6.1 Criterium Inc.: Company Snapshot
18.6.2 Criterium Inc.: Company Overview
18.6.3 Criterium Inc.: Services Portfolio
18.6.4 Criterium Inc.: Recent Developments
18.7 Accell Clinical Research, LLC
18.7.1 Accell Clinical Research, LLC: Company Snapshot
18.7.2 Accell Clinical Research, LLC: Company Overview
18.7.3 Accell Clinical Research, LLC: Services Portfolio
18.7.4 Accell Clinical Research, LLC: Recent Developments
18.8 Charles River Laboratories International
18.8.1 Charles River Laboratories: Company Snapshot
18.8.2 Charles River Laboratories: Company Overview
18.8.3 Charles River Laboratories: Financial Overview
18.8.4 Charles River Laboratories: Services
18.8.5 Charles River Laboratories: Recent Developments
18.9 Medpace, Inc.
18.9.1 Medpace Inc.: Company Snapshot
18.9.2 Medpace Inc.: Company Overview
18.9.3 Medpace Inc.: Financial Overview
18.9.4 Medpace Inc.: Services Portfolio
18.9.5 Medpace Inc.: Recent Developments
18.10 WuXi AppTec
18.10.1 WuXi AppTec: Company Snapshot
18.10.2 WuXi AppTec: Company Overview
18.10.3 WuXi AppTec: Financial Overview
18.10.4 WuXi AppTec: Services Portfolio
18.10.5 WuXi AppTec: Recent Developments
18.11 Syneos Health
18.11.1 Syneos Health: Company Snapshot
18.11.2 Syneos Health: Company Overview
18.11.3 Syneos Health: Financial Overview
18.11.4 Syneos Health: Services Portfolio
18.11.5 Syneos Health: Recent Developments
19. Conclusions
19.1 CRO Regulatory Services for Generics and Biosimilars Drugs: Global Market, 2020-2030
19.2 Leading National Markets for CRO Regulatory Services for Generics and Biosimilars Drugs 2020-2030
19.3 Leading Companies in the CRO Regulatory Services for Generics
and Biosimilars Drugs 2020-2030
List of Figures
Figure 1 CRO Regulatory Services For Generics And Biosimilars Drugs Segmentation By Service, 2019
Figure 2 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Overview
Figure 3 Porter’s Five Forces Analysis
Figure 4 Porter’s Five Force Analysis of the CRO Regulatory Services for Generics and Biosimilar Drugs Market, 2019
Figure 5 SWOT Analysis
Figure 6 PEST Analysis
Figure 7 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
Figure 8 “V” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
Figure 9 “U” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
Figure 10 “W” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
Figure 11 “L” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
Figure 12 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Share(%), By Service 2020, 2025, & 2030
Figure 13 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Share(%), By Region 2020, 2025, & 2030
Figure 14 Global CRO Regulatory Services for Generics and Biosimilars Drugs Market, By Services: Revenues (%), 2020, 2025, & 2030
Figure 15 Global Regulatory Writing and Publishing Market Forecast: Revenue ($bn) and AGR (%), 2019-2030



★調査レポート[ジェネリック医薬品・バイオシミラー医薬品用CRO規制サービスの世界市場2020-2030] (コード:VGA20DE021)販売に関する免責事項を必ずご確認ください。
★調査レポート[ジェネリック医薬品・バイオシミラー医薬品用CRO規制サービスの世界市場2020-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆